Vaccine News and Research

Latest Vaccine News and Research

NCQA reports two new findings on nation's health care

The new State of Health Care Quality report from the National Committee for Quality Assurance (NCQA) has two new findings about the nation's health care.

13 Oct 2010

Medicago and PATH partner on development of broad coverage influenza vaccine

Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded $946,000 in funding by U.S.-based PATH pursuant to a research collaboration agreement. Medicago and PATH will work together on a broad coverage influenza vaccine based on Medicago's proprietary plant-based Virus-Like Particle (VLP) technologies for the developing world.

13 Oct 2010

ImmunoCellular develops ICT-107 cell-based vaccine for GBM treatment

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it has developed an innovative method for manufacturing the company's lead product candidate, ICT-107, a dendritic cell-based vaccine for the treatment of glioblastoma multiforme (GBM).

13 Oct 2010

First Edition: October 13, 2010

Today's early morning highlights from major news organizations looks at the number of people denied health coverage by major insurers, arguments before the Supreme Court on the right to sue vaccine makers, concerns about the FDA's plans on reviewing medical devices and doctors moving from private practice to hospital work.

13 Oct 2010

New global plan for elimination of TB

The world could be on its way towards eliminating tuberculosis (TB) if governments and donors fully invest in a plan released today by the Stop TB Partnership. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis for the first time identifies all the research gaps that need to be filled to bring rapid TB tests, faster treatment regimens and a fully effective vaccine to market.

13 Oct 2010

$1.5 million DOD award allows U-M scientists to pursue new application for nanoemulsion technology

The U.S. Department of Defense has awarded $1.5 million over three years to the Michigan Nanotechnology Institute for Medicine and Biological Sciences and to Ann Arbor-based NanoBio Corporation to develop and test nanoemulsions with potential to fight a wide range of wound infections, including drug-resistant forms.

13 Oct 2010

LifeWise improves access to common immunizations at pharmacies

LifeWise Health Plan of Oregon is announcing a new step to remove barriers to care by providing improved access to common immunizations at pharmacies. LifeWise members can now simply present their member card at a pharmacy just as they do at their doctor's office to receive immunizations.

13 Oct 2010

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today it has received approval from the first Taiwanese Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Oct 2010

High Court to hear vaccine case

The New York Times: A Supreme Court case scheduled for today will examine whether the 1986 National Childhood Vaccine Injury Act should protect manufacturers from "virtually all product liability lawsuits."

13 Oct 2010

Vaccine lawsuits – Justices divided

The US Supreme Court is seemingly divided over the lawsuits on childhood vaccines. The Justices acquiesced that the Congress has done its bit to shield vaccine-makers from suits by the few who have had an adverse reaction to a vaccine approved by the Food and Drug Administration. Now the matter revolves around whether those hurt by vaccines have the right to sue manufacturers if they can prove that a safer version was available.

12 Oct 2010

First Edition: October 12, 2010

Today's early morning highlights from major news organizations look at a probe of a California hospital chain, the effect that the governors' races around the country will have on the federal health law and a review of prescription purchases that shows more Americans are foregoing their medicines.

12 Oct 2010

Parents rate research on safety of vaccines and medications given to children as most important

Each year, hundreds of millions of public and private dollars are spent on medical research to improve the health of children – yet parents have little input regarding how those dollars should be spent.

12 Oct 2010

Older people who do not get vaccinated rely on indigenous health practices

Eating steamed pears, having a soothing massage or bathing in a herbal mixture are just some of indigenous health practices used by older people to ward off or treat influenza, according to research published in the October issue of the Journal of Advanced Nursing.

12 Oct 2010

Scripps Research study findings could transform drug development to produce more effective treatments

Scientists from The Scripps Research Institute have uncovered new evidence that challenges the current theory about a process key to the way modern drugs are designed and how they work in the human body.

12 Oct 2010

Mammography, vaccines still raise questions in consumers' minds

NPR reports on two preventive measures that, despite years of research, still have consumers wondering what to do.

12 Oct 2010

Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors

Merck Serono, a division of Merck KGaA, Darmstadt, Germany has announced that new data presented today at the 35th Congress of the European Society for Medical Oncology (ESMO) have shown that patients with KRAS wild-type metastatic colorectal cancer (mCRC) who experienced early tumor shrinkage (within 8 weeks) during 1st line Erbitux (cetuximab) based treatment lived a median of 28.3 months.

12 Oct 2010

Loyola continues mandatory employee flu-vaccination policy for second straight year

The best way to prevent the spread of the flu to patients in a medical setting would be to require all health-care workers to get an annual flu shot, says the American Academy of Pediatrics.

12 Oct 2010

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.

11 Oct 2010

Generex to acquire majority interest in Global Medical Direct

Generex Biotechnology Corporation today announced that it has entered into a definitive agreement to acquire a majority interest (51%) in Global Medical Direct, LLC of Lenexa, Kansas, a nationwide Durable Medical Equipment and Pharmaceutical provider specializing in direct-to-consumer diabetes supplies and medications.

11 Oct 2010

Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury

Geron Corporation today announced the enrollment of the first patient in the company's clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1. The primary objective of this Phase I study is to assess the safety and tolerability of GRNOPC1 in patients with "complete" American Spinal Injury Association (ASIA) Impairment Scale grade A thoracic spinal cord injuries. Participants in the study must be newly injured and receive GRNOPC1 within 14 days of the injury.

11 Oct 2010

Vaccine News and Research

Latest Vaccine News and Research

NCQA reports two new findings on nation's health care

Medicago and PATH partner on development of broad coverage influenza vaccine

ImmunoCellular develops ICT-107 cell-based vaccine for GBM treatment

First Edition: October 13, 2010

New global plan for elimination of TB

$1.5 million DOD award allows U-M scientists to pursue new application for nanoemulsion technology

LifeWise improves access to common immunizations at pharmacies

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

High Court to hear vaccine case

Vaccine lawsuits – Justices divided

First Edition: October 12, 2010

Parents rate research on safety of vaccines and medications given to children as most important

Older people who do not get vaccinated rely on indigenous health practices

Scripps Research study findings could transform drug development to produce more effective treatments

Mammography, vaccines still raise questions in consumers' minds

Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors

Loyola continues mandatory employee flu-vaccination policy for second straight year

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Generex to acquire majority interest in Global Medical Direct

Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Vaccine News and Research

Latest Vaccine News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in